WFRF:(Mantzoros Christos)
Sökning: WFRF:(Mantzoros Christos) > Genome-wide associa...
LIBRIS Formathandbok (Information om MARC21)
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04941naa a2200469 4500 | |
| 001 | oai:DiVA.org:uu-487626 | |
| 003 | SwePub | |
| 008 | 221031s2022 | |||||||||||000 ||eng| | |
| 009 | oai:prod.swepub.kib.ki.se:150931986 | |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4876262 URI |
| 024 | 7 | a https://doi.org/10.1016/j.metabol.2022.1553292 DOI |
| 024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1509319862 URI |
| 040 | a (SwePub)uud (SwePub)ki | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Larsson, Susanna C.u Karolinska Institutet,Uppsala universitet,Medicinsk epidemiologi,Karolinska Inst, Unit Cardiovasc & Nutr Epidemiol, Inst Environm Med, Stockholm, Sweden.4 aut0 (Swepub:uu)susla720 |
| 245 | 1 0 | a Genome-wide association and Mendelian randomization study of fibroblast growth factor 21 reveals causal associations with hyperlipidemia and possibly NASH |
| 264 | 1 | b Elsevier,c 2022 |
| 338 | a electronic2 rdacarrier | |
| 500 | a Correction in: Metabolism, Volume 143, June 2023, Pages 155555DOI: 10.1016/j.metabol.2023.155555 | |
| 520 | a Background: Fibroblast growth factor 21 (FGF21) is a hepatokine that produces metabolic benefits, such as improvements of lipid profile. We performed a genome-wide association study (GWAS) to identify genetic variants associated with circulating FGF21 and investigated the causal effects of FGF21 on pertinent outcomes using Mendelian randomization (MR).Methods: We conducted a GWAS testing similar to 7.8 million DNA sequence variants with circulating FGF21 in a discovery cohort of 6259 Swedish adults with replication in 4483 Swedish women. We then performed two-sample MR analyses of genetically predicted circulating FGF21 in relation to alcohol and nutrient intake, cardiovascular and metabolic biomarkers and diseases, and liver function biomarkers using publicly available GWAS summary statistics data.Results: Our GWAS identified multiple single-nucleotide polymorphisms with genome-wide significant associations (P < 5 x 10(-8)) with circulating FGF21 on chromosomes 2 and 19 in or near the GCKR and FGF21 genes, respectively. The strongest signal at the FGF21 locus (rs2548957, beta = 0.181, P < 2.18 x 10(-42)) displayed in twosample MR analyses robust associations with lower alcohol intake, lower circulating low-density lipoprotein cholesterol, apolipoprotein B, C-reactive protein, gamma-glutamyl transferase, and galectin-3 concentrations, and higher circulating insulin-like growth factor-I and alkaline phosphatase concentrations after correcting for multiple testing (P < 0.0018) whereas associations with fat mass, type 2 diabetes, and cardiovascular disease were largely null.Conclusions: We identified robust associations of certain genetic variants in or near the GCKR and FGF21 genes with circulating FGF21 concentrations. Furthermore, our results support a strong causal effect of FGF21 on improved lipid profile, reduced alcohol consumption and C-reactive protein concentrations, and liver function biomarkers including fibrosis. We found largely null or weak positive associations with fat mass, diabetes, and cardiovascular disease as well as higher insulin-like growth factor-I concentrations, which could indicate a compensatory increase to regulate the above FGF21 resistant states in humans. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng |
| 653 | a Fibroblast growth factor 21 | |
| 653 | a Alkaline phosphatase | |
| 653 | a Genome-wide association study | |
| 653 | a Hepatokine | |
| 653 | a Mendelian randomization | |
| 653 | a Single-nucleotide polymorphisms | |
| 700 | 1 | a Michaëlsson, Karl,d 1959-u Uppsala universitet,Medicinsk epidemiologi4 aut0 (Swepub:uu)karlmich |
| 700 | 1 | a Mola-Caminal, Marinau Uppsala universitet,Medicinsk epidemiologi4 aut0 (Swepub:uu)marmo445 |
| 700 | 1 | a Höijer, Jonasu Uppsala universitet,Medicinsk epidemiologi4 aut0 (Swepub:uu)jonho616 |
| 700 | 1 | a Mantzoros, Christos S.u Harvard Med Sch, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.;Harvard Med Sch, Sect Endocrinol, VA Boston Healthcare Syst, Boston, MA 02115 USA.4 aut |
| 710 | 2 | a Uppsala universitetb Medicinsk epidemiologi4 org |
| 773 | 0 | t Metabolismd : Elsevierg 137q 137x 0026-0495x 1532-8600 |
| 856 | 4 | u https://doi.org/10.1016/j.metabol.2022.155329y Fulltext |
| 856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1707527/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-487626 |
| 856 | 4 8 | u https://doi.org/10.1016/j.metabol.2022.155329 |
| 856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:150931986 |
Hitta mer i SwePub
- Av författaren/redakt...
- Larsson, Susanna ...
- Michaëlsson, Kar ...
- Mola-Caminal, Ma ...
- Höijer, Jonas
- Mantzoros, Chris ...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Endokrinologi oc ...
- Artiklar i publikationen
- Metabolism
- Av lärosätet
- Uppsala universitet
- Karolinska Institutet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
